Acrivon Therapeutics Inc (ACRV): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Acrivon Therapeutics (ACRV) - corporate logo

This price visualization for Acrivon Therapeutics (ACRV) assisting in the basic asset valuation demonstrates the 0.00 metric, which correlates with the development of the AP3 platform and the potential of ACR-368. Acrivon Therapeutics (ACRV) is automating volunteer recruitment for trials via the APRYSE AI service, replacing manual map analysis with digital solutions. Stable management is effectively conducting trials, leveraging their authority in precision oncology and the support of major pharmaceutical partners.

Acrivon - ACRV Company Value to EBITDA (period 11/23/2025 - 11/12/2026)

Metric breakdowns and analytics for acrivon.com (ACRV)

- current price and projected stock value:
Stock Price Acrivon|ACRV - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Acrivon Pharma|ACRV - Business Value
- book value of equity indicators:
Book Value per Share Acrivon Therapeutics|ACRV - Total Stockholders' Equity|Market Value to Book Value Ratio acrivon.com|ACRV - Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Acrivon Therapeutics|ACRV - Long-Term Debt to Capital|Short-Term Debt to Equity Acrivon Therapeutics, Inc.|ACRV - Company Total Debt Obligations|Debt to Book Value Acrivon Pharma|ACRV - Company Long-Term Loans and Borrowings|Company Short-Term Debt Acrivon Therapeutics|Quick Liquidity acrivon.com
- financial results and valuation multiples details:
ACRV - Company Profit|Projected Future Earnings Acrivon Therapeutics|ACRV - Price to Earnings Ratio|Future Price to Earnings Acrivon Therapeutics|ACRV - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acrivon Pharma|ACRV - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Acrivon Therapeutics|ACRV - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth acrivon.com|ACRV - Net earnings per share change in current year|Expected earnings per share growth for next year Acrivon Therapeutics
Comprehensive company analysis:Acrivon (ACRV)
Manufactured products of Acrivon Therapeutics, Inc.

Acrivon Therapeutics' leadership in precision oncology via the AP3 platform requires capital-intensive investments, making the analysis of total enterprise value relative to operating profit critically important. The company's EV/EBITDA history demonstrates the market valuation of the enterprise adjusted for net debt, allowing investors to determine the extent of the premium paid for technological potential and compare asset value with actual cash flow generation efficiency.

Key competitors

EV/EBITDA Multiple NVCR (NovoCure Corp)|EV/EBITDA Multiple Alpha Tau Corp DRTS|FBIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ALLR (Allarity Therapeutics) - Enterprise Value to Operating Income Before Depreciation